ALGI-MABO
As listed in the register: ALGI-MABO 0,4 G/ML SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN
2g · solución inyectable
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Metamizol
- Made by
- Mabo Farma S.A.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
Regulator safety notice · 2024-09-18
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
Measures to minimise serious outcomes of known side effect with painkiller metamizole
On 18 September 2024, the CMDh endorsed the measures recommended by EMA’s safety committee, PRAC, to minimise the serious outcomes of agranulocytosis, a known side effect caused by the painkiller metamizole.
Agranulocytosis involves a sudden and sharp decrease in granulocytes, a type of white blood cell, that can lead to serious or even fatal infections.
The committee recommended that healthcare professionals must inform patients to stop taking these medicines and seek immediate medical attention if they develop symptoms of agranulocytosis.
These include fever, chills, sore throat and painful sores on the moist, inner body surfaces (mucosa), especially in the mouth, nose and throat or in the genital or anal regions.
Patients must remain alert for these symptoms both during and shortly after stopping treatment.
The PRAC concluded that the benefits of metamizole medicines continue to outweigh the risks.
Quoted from: European Medicines Agency — Metamizole-containing medicinal products, referral · retrieved 2026-09-30
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Details
| Made by | Mabo Farma S.A. |
|---|---|
| Active substance | Metamizol |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 2g |
| Form | solución inyectable |
| Classification | N02BB · Pain, sleep, mood, epilepsy and the brain |
| Route | vía intramuscular, vía intravenosa, vía oral |
| Marketed | Yes, according to the register |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | ALGI-MABO 0,4 G/ML SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN |
| Nº Registro | 51345 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solución inyectable1 products
- 2g
- cápsula dura1 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.